Trump to Nominate Scott Gottlieb to Lead FDA Doctor has promoted views that in some cases would mean less regulation from the agency By Thomas M. Burton See note please
Posted By Ruth King on March 10th, 2017
https://www.wsj.com/articles/trump-expected-to-nominate-scott-gottlieb-to-lead-fda-1489172182
We cannot have faster approval for new drugs unless we have serious tort reform….pharma companies have to contend with litigations, which, in some cases have no statute of limitations ….rsk
President Donald Trump plans to nominate Scott Gottlieb, a conservative thinker and medical doctor with previous government experience, to run the Food and Drug Administration, the White House said Friday.
Dr. Gottlieb, who has ties to the drug industry, previously served as deputy FDA commissioner under President George W. Bush.
Dr. Gottlieb also is a frequent contributor to The Wall Street Journal opinion pages and a prolific writer on FDA topics. He has promoted provocative views that in some cases would mean less regulation from the nation’s leading medical-products and food-supervisory agency.
His views appear aligned with those of the Trump administration, especially since Dr. Gottlieb generally favors faster product approvals. Mr. Trump has described the FDA product-approval process as “slow and burdensome.”Dr. Gottlieb supports the core mission of the FDA, and he has long experience with the medical and legal principles he would deal with in the job, which likely would ease his path to Senate confirmation. He is a cancer survivor who is a 1994 graduate of Wesleyan University and holds a 1999 M.D. degree from the Mount Sinai School of Medicine in New York.
Dr. Gottlieb wins plaudits from people of different political backgrounds. Kavita Patel, a doctor and former Obama administration official now with the Brookings Institution, said, “I found that even when I would occasionally disagree with him on policy, I appreciated that he would take the time to listen.”
Dr. Gottlieb could bring significant changes to the FDA. He wrote in a recent piece in National Affairs that decisions on new drugs should ultimately be made not by the current group of drug reviewers but by a “central committee that is comprised of the agency’s most senior scientists.” CONTINUE AT SITE
Comments are closed.
